MediWound has commenced a pivotal, multicentre Phase III VALUE trial to assess its bioactive debridement therapy, EscharEx, ...

US-based biotechnology company Rallybio has dosed the first subject in a Phase II trial evaluating RLYB212 as a potential ...

Clinical trials can assist you in getting the right treatment for your condition. Before you consider it, here's what you should know.

with hints of efficacy and a boatload more patients in phase 1 waiting for more evaluation. On balance, at these price levels, VIR stock is attractive, though risky. Vir Biotechnology (NASDAQ ...

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...

Dr. Xiaohu Zhang, co-founder and CEO of Accropeutics said, “Dosing of the first patient in AC-101’s Phase 1b study represents a significant step towards advancing this novel oral therapeutic for ...

CHICAGO--(BUSINESS WIRE)-- MAIA Biotechnology, Inc., (NYSE American ... The single arm pivotal Phase 2 trials will study the drug combination in hepatocellular carcinoma (HCC), small cell lung ...

PDS Biotechnology (PDSB) reaffirmed the Company’s guidance of initiating its VERSATILE-003 Phase 3 clinical trial of Versamune HPV plus ...

A successful biotechnology manager must know what to expect during the early stages of a startup and be eager to fight to overcome obstacles. Our experience tells us, for example, that candidates ...

“We are enthusiastic about getting patients started in the OCU200 Phase 1 clinical trial and sharing not only safety but preliminary efficacy data as the study progresses,” said Dr. Huma Qamar, Chief ...

For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944. About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company ...